-+ 0.00%
-+ 0.00%
-+ 0.00%
Zoetis (ZTS) Could Be 9% Undervalued Following Cytopoint Plus USDA License
Share
Listen to the news

Why Cytopoint Plus matters for Zoetis

Zoetis (ZTS) just picked up a USDA license for Cytopoint Plus, a next generation monoclonal antibody that delivers 75 day allergic itch relief for dogs in a single injection.

This product extends the dermatology range that already includes Cytopoint and Apoquel and directly targets one of the biggest practical issues in chronic canine allergy care: treatment adherence tied to frequent clinic visits.

Zoetis shares trade at US$84.39 and have picked up short term momentum, with a 30 day share price return of 6.31% and a 90 day gain of 14.10%. However, total shareholder return has fallen 27.36% over one year and almost 60% over five years, which suggests recent product news like Cytopoint Plus is being weighed against a longer period of weaker sentiment.

Scan how Zoetis compares with other veterinary and pharma plays gaining fresh product catalysts by reviewing our curated 19 high quality undiscovered gems in this corner of the market.

Zoetis has just put a fresh product story on the table, yet the share price only recently clawed back some long-term losses. Is most of the easy re-rating already spent, or does the valuation still suggest room to run next?

Most Popular Narrative: 9% Undervalued

On Simply Wall St, the most followed narrative pegs Zoetis at a fair value of $92.92 versus the latest close of $84.39, which points to a moderate discount according to that author. ValueInvestingSubstack, a Simply Wall St Community investor who wrote the narrative, frames Zoetis as a mature animal health business with measured growth and a focus on pets.

The company was spun-off from Pfizer in 2013 as the “animal pharma” division, and basically makes medicines for pets and livestock. The pet division, which they call the “Companion Animal” segment, does about $6.5B in revenues, with most of it coming from Dogs and Cats.

Think of allergies or diabetes in pets, serious illnesses which warrant pharmaceutical treatment and an expense that households are willing to spend on a “family member”. That’s what Zoetis addresses in a nutshell together with its army of veterinarian clinics across the world.

See why 28 investors see Zoetis as 9% undervalued.

The narrative applies a 7.108% discount rate and arrives at that $92.92 estimate while characterizing earnings growth in the high single digits and the overall business as relatively steady rather than high growth. That framing helps explain why Zoetis is viewed as modestly undervalued instead of deeply mispriced, and it also ties directly into the focus on established product franchises like dermatology, parasiticides, and chronic pet therapies.

Result: Fair Value of $92.92 (UNDERVALUED)

Still, two pressure points could upset that 9% undervalued story: further weakness in US Companion Animal demand and any earnings drag from debt funded buybacks.

Find out about the key risks to this Zoetis narrative.

Next Steps

Mixed messages in the Zoetis story today, with fresh product momentum but a challenging long term share record, mean you should stress test both sides of the case yourself. To weigh the key concerns against the potential upside in one place, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zoetis?

If the Zoetis story has you thinking about where to put fresh capital next, do not stop with a single ticker. Broaden your watchlist using targeted screeners built to surface different edges across quality, value, income, and resilience.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending